Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een studie van subcutane (SC) toediening van Amivantamab voor de behandeling van geavanceerde solide maligniteiten (PALOMA)

2 november 2026 bijgewerkt door: Janssen Research & Development, LLC

Een open-label, multicenter, dosisescalatie fase 1b-onderzoek om de veiligheid en farmacokinetiek te beoordelen van subcutane toediening van amivantamab, een menselijk bispecifiek EGFR- en cMet-antilichaam voor de behandeling van gevorderde solide maligniteiten

The purpose of this study is to assess the feasibility of subcutaneous (SC) administration of amivantamab based on safety and pharmacokinetics and determine a dose, dose regimen and formulation for amivantamab SC delivery.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Werkelijk)

158

Fase

  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Ontario
      • Toronto, Ontario, Canada, M5G 2M9
        • University Health Network
      • Manchester, Verenigd Koninkrijk, M20 4BX
        • The Christie Nhs Foundation Trust
      • Sutton, Verenigd Koninkrijk, SM2 5PT
        • Royal Marsden Hospital
    • California
      • West Hollywood, California, Verenigde Staten, 90048
        • Cedars Sinai Medical Center
    • Indiana
      • Indianapolis, Indiana, Verenigde Staten, 46256
        • Community Health Network
    • New York
      • New York, New York, Verenigde Staten, 10016
        • Langone Health at NYC University, NYU School of Medicine
    • Oregon
      • Portland, Oregon, Verenigde Staten, 97213
        • Providence Portland Medical Center
    • Tennessee
      • Nashville, Tennessee, Verenigde Staten, 37203
        • Sarah Cannon Research Institute
      • Cheongju-si, Zuid -Korea, 28644
        • Chungbuk National University Hospital
      • Seongnam-si, Zuid -Korea, 13620
        • Seoul National University Bundang Hospital
      • Seoul, Zuid -Korea, 03722
        • Severance Hospital Yonsei University Health System
      • Seoul, Zuid -Korea, 06351
        • Samsung Medical Center

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion criteria:

  • Part 1 and Part 2: Participant must have histologically or cytologically confirmed solid malignancy that is metastatic or unresectable and which may derive benefit from epidermal growth factor receptor (EGFR) or mesenchymal-epidermal transition tyrosine kinase receptor/hepatocyte growth factor receptor (cMet) directed therapy. Eligible tumor types include non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), hepatocellular cancer (HCC), colorectal cancer (CRC), renal cell cancer (RCC), medullary thyroid cancer (MTC), gastroesophageal cancer (GEC), mesothelioma, breast cancer (BC) and ovarian cancer (OC). Participants must have either progressed after prior standard of care therapy for metastatic disease, be ineligible for, or have refused all other currently available therapeutic options. In cases where participants refuse currently available therapeutic options, this must be documented in the study records.
  • Participant must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • A woman of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) at Screening and a negative urine or serum pregnancy test within 24 hours before the first dose of study drug
  • A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 6 months after receiving the last dose of study drug
  • A man who is sexually active with a woman of childbearing potential must agree to use a condom and his partner must also be practicing a highly effective method of contraception (that is, established use of oral, injected or implanted hormonal methods of contraception; placement of an Intrauterine device [IUD] or Intrauterine system [IUS])

Exclusion criteria:

  • Participant has uncontrolled inter-current illness, including but not limited to poorly controlled hypertension or diabetes, ongoing or active systemic infection (that is, has discontinued all antibiotics for at least one week prior to first dose of study drug), diagnosed or suspected viral infection (except Human immunodeficiency virus [HIV] positive participants with 1 or more of the following: a) not receiving highly active antiretroviral therapy; b) a change in antiretroviral therapy within 6 months of the start of screening; c) cluster of differentiation 4 (CD4)+ T-cell count less than [<]350 per cubic millimeters [mm^3] at screening; d) an acquired immunodeficiency syndrome-defining opportunistic infection within 6 months of the start of screening), or psychiatric illness/social situation that would limit compliance with study requirements, including ability to self-care for anticipated toxicities [that is. rash or paronychia]. Participants with medical conditions requiring chronic continuous oxygen therapy are excluded
  • Participant has had prior chemotherapy, targeted cancer therapy, or treatment with an investigational anti-cancer agent within 2 weeks or 4 half-lives, whichever is longer, before the first administration of study drug; or participant has received prior immunotherapy within 6 weeks before the first administration of study drug. For agents with long half-lives, the maximum required time since last dose is 4 weeks. Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less, (except for alopecia [any grade], Grade less than or equal to [<=] 2 peripheral neuropathy, and Grade less than [<] 2 hypothyroidism stable on hormone replacement). Autoimmune toxicities from previous immunotherapy must be fully resolved to baseline levels
  • Participants with untreated brain metastases. Participants with locally treated metastases that are clinically stable and asymptomatic for at least 2 weeks and who are off or receiving low-dose corticosteroid treatment (<=10 milligrams [mg] prednisone or equivalent) for at least 2 weeks prior to study treatment are eligible
  • Participant has an active malignancy other than the disease under study requiring treatment
  • Participant has leptomeningeal disease

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Part 1: Ami-LC-MD and Ami-LC

Participants in cohort 1a will receive amivantamab admixed with rHuPH20 (Ami-LC-MD) subcutaneous (SC) infusion and participants in cohort 1b will receive amivantamab (Ami-LC) SC infusion.

Participants will receive amivantamab admixed with rHuPH20 SC infusion.

Participants will receive amivantamab SC infusion.

Experimenteel: Part 2: Ami-HC and Ami-HC-CF

Participants will receive SC infusion of newly developed high concentration amivantamab (Ami-HC) or SC injection of amivantamab co-formulated with rHuPH20 (Ami-HC-CF).

Participants will receive amivantamab SC infusion.

Participants will receive amivantamab co-formulated with rHuPH20 as SC injection.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Observed Amivantamab Serum Concentration Immediately Prior to the Next Dose Administration (Ctrough)
Tijdsspanne: Up to Day 29

Ctrough is the observed amivantamab serum concentration immediately prior to the next drug administration.

Up to Day 29
Number of Participants with Adverse Event (AE)
Tijdsspanne: Up to 4 years 1 month

An adverse event is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the drug. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.

Up to 4 years 1 month
Number of Participants with Dose Limiting Toxicity (DLT)
Tijdsspanne: Up to Day 28

Number of participants with DLT will be assessed.

Up to Day 28
Number of Participants with Clinical Laboratory Abnormalities
Tijdsspanne: Up to 4 years 1 month

Number of participants with clinical laboratory (hematology, clinical chemistry, and urinalysis) abnormalities will be assessed.

Up to 4 years 1 month

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of Participants with Anti-amivantamab and Anti-rHuPH20 antibodies
Tijdsspanne: Up to 4 years 1 month

Number of participants with anti-amivantamab and anti-rHuPH20 antibodies will be assessed.

Up to 4 years 1 month
Epidermal Growth Factor Receptor (EGFR) Concentrations
Tijdsspanne: Up to 4 years 1 month

EGRF concentrations markers will be assessed.

Up to 4 years 1 month
Mesenchymal-Epidermal Transition Tyrosine Kinase Receptor/Hepatocyte Growth Factor Receptor (cMET) Markers
Tijdsspanne: Up to 4 years 1 month

cMET markers will be analyzed.

Up to 4 years 1 month
Overall Response Rate (ORR)
Tijdsspanne: Up to 4 years 1 month

ORR defined as the proportion of participants with partial response (PR) or better according to Response Criteria in Solid Tumors (RECIST) v1.1.

Up to 4 years 1 month
Part 2: Maximum Amivantamab Dosing Interval Between Time Zero to Steady State
Tijdsspanne: Up to 4 years 1 month

Maximum amivantamab dosing interval Between time zero to steady state will be assessed.

Up to 4 years 1 month

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

10 november 2020

Primaire voltooiing (Werkelijk)

11 juli 2024

Studie voltooiing (Geschat)

1 april 2027

Studieregistratiedata

Eerst ingediend

6 oktober 2020

Eerst ingediend dat voldeed aan de QC-criteria

22 oktober 2020

Eerst geplaatst (Werkelijk)

28 oktober 2020

Updates van studierecords

Laatste update geplaatst (Werkelijk)

3 november 2026

Laatste update ingediend die voldeed aan QC-criteria

2 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • CR108891
  • 2020-003225-36 (EudraCT-nummer)
  • 61186372NSC1003 (Andere identificatie: Janssen Research & Development, LLC)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren